Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Morpholine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GABRP | O00591 | 1/20 | 0.35 |
| ▸ | GABRD | O14764 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Morpholine SCHEMBL29207396 | 1.00 | KMT2A (0.58) | KMT2AMEN1KDM4EGAACYP2C9 | |
| Acetic Acid SCHEMBL10708681 | 0.97 | MEN1 (0.63) | KMT2AMEN1KDM4EGAACYP2C9 | |
| Morpholine SCHEMBL29076892 | 0.97 | KMT2A (0.55) | KMT2AMEN1KDM4EGAACYP2C9 | |
| Acetic Acid SCHEMBL10707147 | 0.97 | MEN1 (0.63) | KMT2AMEN1KDM4EGAACYP2C9 | |
| Acetic Acid SCHEMBL28048691 | 0.97 | KDM4E (0.63) | KMT2AMEN1KDM4EGAACYP2C9 | |
| Morpholine SCHEMBL15572639 | 0.95 | MEN1 (0.52) | KMT2AMEN1KDM4EGAACYP2C9 | |
| Morpholine SCHEMBL15572290 | 0.95 | MEN1 (0.52) | KMT2AMEN1KDM4EGAACYP2C9 | |
| Morpholine SCHEMBL27737341 | 0.92 | GAA (0.61) | KMT2AMEN1KDM4EGAACYP2C9 | |
| Morpholine SCHEMBL15510851 | 0.91 | MEN1 (0.48) | KMT2AMEN1KDM4EGAACYP2C9 | |
| Morpholine SCHEMBL28632200 | 0.91 | KMT2A (0.48) | KMT2AMEN1KDM4EGAACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 440 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110964085-B | Preparation method of carfilzomib and derivatives thereof | 扬子江药业集团有限公司 | 2023-07-07 | — | — | CN | claimed |
| CN-114524721-A | Synthesis process of methacrolein | 郑州中科新兴产业技术研究院 | 2022-05-24 | — | — | CN | claimed |
| CN-113786711-A | Method for recovering chlorine-containing volatile organic compounds in organic waste gas by using ionic liquid | 郑州中科新兴产业技术研究院 | 2021-12-14 | — | — | CN | claimed |
| US-10464958-B2 | Method for the synthesis of alpha-aminoalkylenephosphonic acid | MONSANTO TECHNOLOGY LLC (US) | 2019-11-05 | — | — | US | claimed |
| CN-108997463-A | A kind of female steroid -4,9- diene -3,17- diketone preparation method | 四川理工学院 | 2018-12-14 | — | — | CN | claimed |
| US-20180346497-A1 | METHOD FOR THE SYNTHESIS OF ALPHA-AMINOALKYLENEPHOSPHONIC ACID | MONSANTO TECHNOLOGY LLC (US) | 2018-12-06 | — | — | US | claimed |
| CN-103205000-B | The preparation and application of ionic liquid | 粟维清 | 2018-06-01 | — | — | CN | claimed |
| EP-3101026-B1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | ONYX THERAPEUTICS INC (US) | 2018-03-28 | — | — | EP | claimed |
| EP-3101026-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | Onyx Therapeutics, Inc. (US) | 2016-12-07 | — | — | EP | claimed |
| US-20150232493-A1 | METHOD FOR THE SYNTHESIS OF ALPHA-AMINOALKYLENEPHOSPHONIC ACID | MONSANTO TECHNOLOGY LLC | 2015-08-20 | — | — | US | claimed |
| EP-1588145-A4 | METHODS, MIXTURES, KITS AND COMPOSITIONS PERTAINING TO ANALYTE DETERMINATION | APPLERA CORP (US) | 2007-05-16 | — | — | EP | claimed |
| US-7195751-B2 | Compositions and kits pertaining to analyte determination | APPLERA CORPORATION (US) | 2007-03-27 | — | — | US | claimed |
| CN-1762596-A | Catalyst system for synthesizing acetic acid by methanol low-pressure carbonylation and its application | SW RES & DESIGN INST CHEM IND (CN) | 2006-04-26 | — | — | CN | claimed |
| CN-1740131-A | Low pressure methanol carboxylating process to synthesize acetic acid | SOUTHWEST CHEMICAL ENGINEERING (CN) | 2006-03-01 | — | — | CN | claimed |
| EP-1588145-A2 | METHODS, MIXTURES, KITS AND COMPOSITIONS PERTAINING TO ANALYTE DETERMINATION | Applera Corporation (US) | 2005-10-26 | — | — | EP | claimed |
| US-20040220412-A1 | Compositions and kits pertaining to analyte determination | APPLE CORPORATION | 2004-11-04 | — | — | US | claimed |
| WO-2004070352-A2 | METHODS, MIXTURES, KITS AND COMPOSITIONS PERTAINING TO ANALYTE DETERMINATION | APPLERA CORPORATION (US) | 2004-08-19 | — | — | WO | claimed |
| US-6028231-A | Process for preparing 2-methyl-4-(2,2,3-trimethyl-cyclopent-3-en-1-yl)-but-2-en-1-ol | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2000-02-22 | — | — | US | claimed |
| WO-1999035219-A1 | HYDRAULIC FLUIDS CONTAINING N-ALKYL MORPHOLINE OR A SALT THEREOF | MACDERMID EUROPE PLC (GB) | 1999-07-15 | — | — | WO | claimed |
| US-4298477-A | Regeneration of cation ion-exchange polishers | NALCO CHEMICAL COMPANY (US) | 1981-11-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220412-A1 | Compositions and kits pertaining to analyte determination | KLK3, SRMS, SHBG | KMT2A 3232/4885MEN1 389/4885KDM4E 4358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.